These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9250283)

  • 41. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Thompson EB; Ferreira-Gonzalez A; Contos MJ; Koshy A; Luketic VA; Sanyal AJ; Mills AS; Garrett CT
    Hepatology; 1997 Sep; 26(3):780-5. PubMed ID: 9303513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.
    Fabris P; Tositti G; Mazzella G; Zanetti AR; Nicolin R; Pellizzer G; Benedetti P; de Lalla F
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1187-93. PubMed ID: 10468700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B.
    Akman SA; Okcu SC; Halicioğlu O; Sutcuoglu S; Anil M; Kizilgunesler A; Bakiler AR
    Pediatr Int; 2007 Dec; 49(6):848-52. PubMed ID: 18045284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.
    Rumi M; Del Ninno E; Parravicini ML; Romeo R; Soffredini R; Donato MF; Wilber J; Russo A; Colombo M
    Hepatology; 1996 Dec; 24(6):1366-70. PubMed ID: 8938163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine.
    Kuloglu Z; Krsaçloglu CT; Kansu A; Erden E; Girgin N
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):564-8. PubMed ID: 18030234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.
    Yamada G; Takatani M; Kishi F; Takahashi M; Doi T; Tsuji T; Shin S; Tanno M; Urdea MS; Kolberg JA
    Hepatology; 1995 Nov; 22(5):1351-4. PubMed ID: 7590646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
    J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF.
    Van Thiel DH; Faruki H; Friedlander L; Fagiuoli S; Caraceni P; Molloy PJ; Kania RJ; Wright HI
    Hepatogastroenterology; 1995; 42(6):907-12. PubMed ID: 8847044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy.
    Van Thiel DH; Friedlander L; Kania RJ; Molloy PJ; Hassanein T; Faruki H
    J Viral Hepat; 1997; 4 Suppl 1():101-6. PubMed ID: 9097287
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group.
    Gómez-Rubio M; Porres JC; Castillo I; Quiroga JA; Moreno A; Carreño V
    J Hepatol; 1990; 11 Suppl 1():S63-7. PubMed ID: 2127790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury.
    Wree A; Dechêne A; Herzer K; Hilgard P; Syn WK; Gerken G; Canbay A
    Digestion; 2011; 84(1):54-9. PubMed ID: 21304237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of ursodeoxycholic acid in acute viral hepatitis.
    Galský J; Bansky G; Holubová T; Kõnig J
    J Clin Gastroenterol; 1999 Apr; 28(3):249-53. PubMed ID: 10192613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major.
    Donohue SM; Wonke B; Hoffbrand AV; Reittie J; Ganeshaguru K; Scheuer PJ; Brown D; Dusheiko G
    Br J Haematol; 1993 Mar; 83(3):491-7. PubMed ID: 8387324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha.
    Bresci G; Parisi G; Banti S; Capzia A
    J Viral Hepat; 1995; 2(3):155-8. PubMed ID: 7493311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report].
    Bernal-Reyes R; Escudero RB
    Rev Gastroenterol Mex; 2002; 67(2):70-5. PubMed ID: 12214337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
    Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
    Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.
    Kappler M; Espach C; Schweiger-Kabesch A; Lang T; Hartl D; Hector A; Glasmacher C; Griese M
    Aliment Pharmacol Ther; 2012 Aug; 36(3):266-73. PubMed ID: 22670841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.